Sahajanand Medical Technologies IPO Day 3: Subscribed 1.02x; QIB Demand at 1.12x
Key Highlights
Sahajanand Medical Technologies IPO (₹335 crore mainboard IPO) was subscribed 1.02x on Day 3 of 3, with QIB at 1.12x.
Last updated: Mon, Oct 19, 2026, 12:00 PM IST · mainboard · & · Day 3 of 3
- Sahajanand Medical Technologies IPO subscribed 1.02x overall on Day 3, up from 0.82x on Day 2
- Total bids: 99,45,556 shares against 97,50,482 shares on offer
- Category-wise: 1.12x, 0.97x, 1.03x, Employee 0.17x
- Price band: ₹327 to ₹344 per share
- The issue closes on Mon, Oct 19, 2026
The Sahajanand Medical Technologies IPO is in its third and final day of bidding. As of 12:00 PM IST on October 19, 2026, the issue has reached an overall subscription multiple of 1.02x. The subscription multiple represents the number of shares bid for divided by the number of shares offered to the public. The QIB category is the most-bid segment at 1.12x. The overall subscription has increased from 0.82x recorded at the end of the second day.
Sahajanand Medical Technologies IPO Status: Day 3
Day-wise subscription
| Day | Date | Total bids (shares) | Bid value at upper band (₹ crore) | Subscribed (x) |
|---|---|---|---|---|
| Day 1 | Thu, Oct 15, 2026 | 33,58,902 | 115.55 | 0.34x |
| Day 2 | Fri, Oct 16, 2026 | 80,43,279 | 276.69 | 0.82x |
| Day 3 | Mon, Oct 19, 2026 | 99,45,556 | 342.13 | 1.02x |
Category-wise subscription
| Category | Shares offered | Day 2 bids | Day 2 (x) | Day 3 bids | Day 3 (x) |
|---|---|---|---|---|---|
| QIB | 27,14,423 | 30,48,700 | 1.12x | 30,48,700 | 1.12x |
| NII | 20,35,818 | 10,37,375 | 0.51x | 19,74,517 | 0.97x |
| of which individual NII | — | 9,35,465 | — | 18,27,586 | — |
| of which corporate NII | — | 39,259 | — | 68,112 | — |
| of which other NII | — | 62,651 | — | 78,819 | — |
| Retail | 47,50,241 | 39,22,933 | 0.83x | 48,81,016 | 1.03x |
| Employee | 2,50,000 | 34,271 | 0.14x | 41,323 | 0.17x |
| Total | 97,50,482 | 80,43,279 | 0.82x | 99,45,556 | 1.02x |
The subscription data shows varying levels of interest across investor groups. The QIB category, which refers to qualified institutional buyers, has bid for 1.12x of its quota. Retail investors have bid for 1.03x of their portion, while NIIs, or non-institutional investors bidding above ₹2 lakh, have reached 0.97x. The employee category remains the least subscribed at 0.17x. The day-on-day increase in total bids is spread across these categories.
Sahajanand Medical Technologies IPO Offer Details
| Field | Value |
|---|---|
| IPO date | Thu, Oct 15, 2026 to Mon, Oct 19, 2026 |
| Listing date | To be announced |
| Face value | ₹1 per share |
| Price band | ₹327 to ₹344 per share |
| Lot size | 43 shares |
| Total issue size | 97,50,482 shares (₹335 crore) |
| Listing at | NSE & BSE |
| Lead managers | Motilal Oswal Investment Advisors Pvt Ltd, Avendus Capital Pvt Ltd., HSBC Securities and Capital Markets (India) Pvt Ltd., Nuvama Wealth Management Ltd. |
| MUFG Intime India Pvt Ltd. |
About Sahajanand Medical Technologies
Sahajanand Medical Technologies Ltd. is an R&D-driven company founded in 2001 that develops Class III and Class C/D medical devices. As per the DRHP, the company focuses on vascular intervention and structural heart procedures. It operates three manufacturing facilities, with two located in India and one in Thailand. The company markets its products across 76 countries. Its portfolio includes coronary stents, coronary balloons, trans-catheter aortic valves, and occluders. is earned primarily through the sale of these devices, alongside other products such as renal stents and peripheral drug-coated balloons.
Sahajanand Medical Technologies Financial Highlights
| Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue from operations (₹ crore) | 1,210.50 | 1,024.88 | 901.60 |
| Total income (₹ crore) | 1,233.87 | 1,037.43 | 908.59 |
| Profit after tax (₹ crore) | 69.08 | 25.15 | -7.35 |
| Net worth (₹ crore) | 695.46 | 565.73 | 540.09 |
| Total borrowings (₹ crore) | 204.46 | 168.46 | 117.99 |
| (₹) | 6.67 | 2.09 | -1.31 |
Revenue from operations grew from ₹1,024.88 crore in FY 2024-25 to ₹1,210.50 crore in FY 2025-26. Profit after tax increased from ₹25.15 crore in FY 2024-25 to ₹69.08 crore in FY 2025-26. The margin improved from 2.45% in FY 2024-25 to 5.71% in FY 2025-26.
Risk Factors as per the DRHP
- The company faces supplier concentration risk, as the top 10 suppliers accounted for 64.37% of total purchases in Fiscal 2025.
- The business is subject to risks from outstanding criminal, tax, and regulatory litigation, which may result in financial penalties or operational restrictions.
- Potential manufacturing disruptions due to regulatory non-compliance pose a risk to the company, as any failure to meet standards could lead to the suspension of production.
- The company faces risks related to the management of inventory and the ability to track demand.
How to Check Sahajanand Medical Technologies IPO Subscription Status
Live bidding figures are published by NSE & BSE while the issue is open. Once it closes, allotment status is published by the registrar, MUFG Intime India Pvt Ltd. (https://in.mpms.mufg.com/).
This article is for information only and is not investment advice. Subscription figures are based on exchange data as of Mon, Oct 19, 2026, 12:00 PM IST and can change. IPO investments are subject to market risks; read the offer document carefully before investing.